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The FGF23 coreceptor αKlotho (αKL) is expressed as a membrane-bound protein (mKL) that forms hetero-
meric complexes with FGF receptors (FGFRs) to initiate intracellular signaling. It also circulates as an endo-
proteolytic cleavage product of mKL (cKL). Previously, a patient with increased plasma cKL as the result of 
a translocation [t(9;13)] in the αKLOTHO (KL) gene presented with rickets and a complex endocrine profile, 
including paradoxically elevated plasma FGF23, despite hypophosphatemia. The goal of this study was to test 
whether cKL regulates phosphate handling through control of FGF23 expression. To increase cKL levels, mice 
were treated with an adeno-associated virus producing cKL. The treated groups exhibited dose-dependent 
hypophosphatemia and hypocalcemia, with markedly elevated FGF23 (38 to 456 fold). The animals also mani-
fested fractures, reduced bone mineral content, expanded growth plates, and severe osteomalacia, with highly 
increased bone Fgf23 mRNA (>150 fold). cKL activity in vitro was specific for interactions with FGF23 and was 
FGFR dependent. These results demonstrate that cKL potently stimulates FGF23 production in vivo, which 
phenocopies the KL translocation patient and metabolic bone syndromes associated with elevated FGF23. 
These findings have important implications for the regulation of αKL and FGF23 in disorders of phosphate 
handling and biomineralization.
Introduction
The bone-derived hormone FGF23 and its coreceptor αKlotho 
(αKL) are critical regulators of systemic phosphate metabolism. 
The αKL gene product is expressed as multiple species; the mem-
brane-bound form (mKL) associates with FGF23 and FGF receptors 
(FGFRs) to signal through the MAPK cascade (1, 2). Two soluble 
species have also been reported, an alternatively spliced secreted 
form (sKL) (exons 1–3 of the 5-exon KL gene) and an endoproteo-
lytic cleavage product of mKL (cKL) (3). Although sKL was identi-
fied as a potential αKL variant, only cKL protein was detectable in 
human and rodent plasma and cerebrospinal fluids (4). The cKL 
form has been implicated in directly mediating renal phosphate 
handling through paracrine activity (5); however, whether endocrine 
effects of cKL occur remains unclear. This possibility is highlighted 
by findings in a patient with a translocation in the αKLOTHO (KL) 
gene (t9;13), who presented with elevated plasma cKL and a ricketic 
phenotype (6). The biochemical and endocrine abnormalities were 
complex and included hypophosphatemia, hypocalcemia, inappro-
priately normal 1,25(OH)2 vitamin D (1,25D), and severe hyperpara-
thyroidism requiring surgical intervention. Of note, this patient also 
had sustained, highly elevated plasma FGF23 (>12 times the upper 
limit of normal), despite marked hypophosphatemia on or off calci-
triol treatment (6). The paradoxically elevated FGF23 in this patient, 
together with a clinical phenotype resembling that of patients with 
severe autosomal dominant hypophosphatemic rickets, X-linked 
hypophosphatemia, and tumor-induced osteomalacia (7), is consis-
tent with cKL functioning to direct the expression of FGF23. The 
goal of this study was to examine the ability of circulating cKL to 
act as an endocrine regulator of phosphate metabolism through 
controlling FGF23 production.
Results and Discussion
Effects of cKL on phosphate metabolism in vivo. To test the role of cKL in 
phosphate metabolism, mouse cKL was delivered to mice through 
adeno-associated virus 2/8 (AAV-cKL) under the regulation of a 
hepatic-specific promoter. Following AAV-cKL treatment, serum 
phosphate was dose-dependently reduced from 2 weeks through 
8 weeks (Figure 1A). The vehicle- and AAV-LacZ–injected mice 
maintained normal serum phosphate, with no significant differ-
ences between these 2 control groups at any time point. Serum cal-
cium was variable between the groups at 2 weeks; however, by 4 to 
8 weeks, the AAV-cKL mice were significantly hypocalcemic (Fig-
ure 1B). The effects of AAV-cKL expression on endocrine regula-
tors of phosphate and calcium handling were next examined. At 
weeks 2 through 8, both of the AAV-cKL groups had increased 
plasma cKL (6 to 13 fold; Figure 1C), consistent with the robust 
detection of cKL in liver lysates by immunoblot (Figure 1C, inset). 
Furthermore, compared with controls, serum FGF23 levels were 
markedly elevated in the AAV-cKL groups (38 to 456 fold; Figure 
1D). At week 2 in the high-dose group and in both the low- and 
high-dose cohorts at week 8, the AAV-cKL–treated mice also exhib-
ited hyperparathyroidism (Figure 1E).
Molecular and skeletal manifestations of cKL expression. Quantita-
tive RT-PCR (qPCR) demonstrated a 150-fold elevation of bone 
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Fgf23 mRNA in the AAV-cKL–treated mice (Figure 2A). The down-
stream targets, Egr1 and c-fos mRNAs, both known to be respon-
sive to FGF23-αKL activity (8, 9), were also upregulated in bone 
(Figure 2B). Kidneys had reduced mRNA expression of the type IIa 
sodium-phosphate cotransporter (Npt2a, also known as Slc34a1; 
Figure 2C) and vitamin D 1α-hydroxylase (Cyp27b1; Figure 2D), 
with elevated vitamin D 24-hydroxylase (Cyp24; Figure 2E) mRNA. 
KL mRNA was not different between groups (Figure 2F). These 
effects are consistent with increased circulating Fgf23 and oppo-
site to findings in animals made hypophosphatemic through 
low-phosphate diet (10). The skeletal changes in the high-dose 
AAV-cKL group were dramatic, as micro-CT (μCT) revealed that 
distal and midshaft femora had significantly reduced bone min-
eral density (BMD) and bone mineral content (BMC), and lumbar 
vertebrae had reduced BMC and total area (Table 1). Further, wid-
ened growth plates were detected in the distal femora and tibias 
(Figure 2G). Radiography revealed lower femoral radiodensity and 
spontaneous fractures (Figure 2H), which were accompanied by 
severe osteomalacia, as evaluated by histopathology (Figure 2I). 
Histomorphometry demonstrated that the amount of mineralized 
trabecular bone was lower in AAV-cKL animals, yet these mice had 
significant nonmineralized tissue, increasing the total amount of 
mineralized and nonmineralized tissue volume to 8-fold higher 
in the AAV-cKL–treated mice compared with that in control mice 
(P < 0.01; Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI64986DS1).
Bioactivity of recombinant cKL. Enhanced cell viability through 
antiapoptotic effects is a known readout for cKL bioactivity 
(11). NIH3T3 cells were treated with increasing concentrations 
of cKL and FGF23 either alone or in combination. Following 
serum withdrawal, the combination of FGF23 plus cKL markedly 
increased cell viability (EC50, 1 nM; Figure 3A) at concentrations 
several orders of magnitude less than those required for either 
FGF23 or cKL alone (EC50, >5 μg/ml; Figure 3A). The effects of 
cKL were specific to FGF23 since treatment with either FGF19 or 
21, endocrine FGFs that interact with the β-Klotho coreceptor, 
did not prevent cell apoptosis (Figure 3B). A pan-FGFR inhibi-
tor, but not its inactive isomer, dramatically decreased the cell 
survival effects of cKL and FGF23, supporting that the actions of 
cKL and FGF23 are FGFR mediated (Figure 3C). Further, follow-
ing transfection of the FGFR-negative cell line L6 with FGFR1c, 
FGF23 plus cKL, but not FGF21 plus cKL, stimulated FGFR1 and 
ERK1/2 phosphorylation (Figure 3D).
These findings show that cKL-dependent stimulation of FGF23 
production “overrides” low serum phosphate, a strong physio-
logical suppressor of FGF23, and is consistent with the clinical 
profile of a described patient with KL translocation (6). In this 
regard, mice exposed to cKL manifested hypophosphatemia (Fig-
Figure 1
Biochemical and endocrine effects of AAV-cKL in vivo. (A) Mice treated with AAV-cKL (3 × 1010 or 1 × 1011 gc per mouse) developed dose-depen-
dent hypophosphatemia by 2 weeks of treatment and (B) hypocalcemia by 4 to 8 weeks (n = 5–8 per group; P < 0.05 vs. AAV-LacZ or vehicle). 
*P ≤ 0.05 vs. vehicle; **P ≤ 0.001 vs. vehicle; #P ≤ 0.05 vs. LacZ; ##P ≤ 0.001 vs. LacZ. (C) cKL ELISA showed dose-dependent increases in serum 
cKL at 2 and 8 weeks of AAV-cKL expression, whereas vehicle and AAV-LacZ controls showed no increases above baseline concentrations 
(n = 5–8 per group; P < 0.05 vs. vehicle and AAV-LacZ). In the inset, the immunoblot shows expression of cKL in AAV-cKL mouse liver compared 
with that of vehicle control (Ctl). β-Actin was used to normalize gel loading. *P < 0.05; **P < 0.001 vs. vehicle and AAV-LacZ. (D) Serum intact 
FGF23 was markedly elevated in the AAV-cKL groups at 2 and 8 weeks (*P < 0.01; **P < 0.005). (E) PTH was also increased in the AAV-cKL 
groups (*P < 0.01). Values are shown as mean ± SEM.
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ure 1A) and hypocalcemia (Figure 1B), with highly elevated bone 
Fgf23 mRNA (Figure 2A) and circulating protein (Figure 1D), with 
metabolic bone disease (Figure 2, G–I). The cKL-treated animals 
also demonstrated hyperparathyroidism (Figure 1E) similar to 
that reported in the patient with KL translocation. Whether this 
effect was due to hypocalcemia (Figure 1B) from FGF23-depen-
dent altered 1,25D metabolism or via direct effects of cKL on the 
parathyroid glands in which αKL is normally expressed remains to 
be determined. cKL has been implicated as a phosphaturic factor 
that functions by directly interacting with kidney Npt2a protein 
to inhibit phosphate reabsorption (5). If the dominant effect of 
cKL was to induce hypophosphatemia independently of FGF23, 
following cKL delivery, the predicted endocrine response would 
be FGF23 suppression. In contrast, the present studies demon-
strated that cKL caused robust increases in Fgf23 mRNA and pro-
tein despite the prevailing hypophosphatemia (Figures 1 and 2). 
Additionally, the renal gene responses for regulators of phosphate 
and vitamin D metabolism were consistent with elevated FGF23 
(Figure 2, C–E) and are reciprocal to those caused by FGF23-inde-
pendent hypophosphatemia. While potent, cKL is not the sole 
regulator of FGF23, as αKL-null mice have elevated FGF23, likely 
driven by 1,25D and/or a yet-identified mechanism for sensing 
hyperphosphatemia. The AAV-cKL–treated mice had severe osteo-
malacia (Figure 2), consistent with the prevailing hypophosphate-
Figure 2
Molecular and skeletal phenotypes with cKL delivery. (A) Fgf23 mRNA was increased in bone harvested from mice 4 weeks following AAV-cKL 
(1 × 1011 gc per mouse) versus controls. (B) Egr1 and c-fos were also elevated in bone following cKL delivery. #P < 0.05 vs. vehicle/LacZ. Reduced 
renal mRNAs for (C) Npt2a and (D) Cyp27b1, with elevated (E) Cyp24. (F) Mice receiving AAV-cKL had no significant change in KL (1 × 1011 gc 
per mouse). *P < 0.05, **P < 0.01 vs. vehicle/LacZ. (A–F) Mean ± SEM; n = 3–5 per group. (G) Compared with controls (left and middle panels), 
AAV-cKL–treated mice (8 weeks) had widened growth plates at the knee (arrows) (original magnification, ×5; ×2 [inset]). (H) Femora from AAV-
cKL–treated mice (12 weeks; 1 × 1011 gc per mouse) showed lower radiodensity and had spontaneous fractures (arrow) compared with those 
from vehicle control mice. (I) Goldners’-stained sections revealed an increase in nonmineralized bone (nm) in the high-dose AAV-cKL mice after 
a 12-week treatment compared with vehicle control. Original magnification, ×10, ×2.5 (inset). ma, marrow.
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mia (Figure 1A), as we detected an increase in total trabecular bone 
driven by an increase in nonmineralized tissue (Supplemental 
Table 1). The activity of cKL was selective for FGF23 (Figure 3), 
which supports the concept of cKL potentially regulating FGF23 
production through cKL-FGF23-FGFR interactions (Figure 3) in 
bone, the primary source of this hormone. Consistent with these 
findings, patients with activating mutations in FGFR1c have ele-
vated plasma FGF23 (12), and reciprocally, suppression of FGFR 
activity inhibits FGF23 production (13). Whether cKL interacts 
specifically with FGFR1c in vivo and whether this system could 
be modulated as a therapeutic target remain to be determined. In 
conclusion, these studies demonstrate that cKL is an important 
factor in regulating FGF23 production and significantly modify 
the current models of phosphate homeostasis, with implications 
for understanding the control of FGF23 expression during normal 
and disordered phosphate handling.
Table 1
μCT analysis of skeletal sites in 8-week-old mice
Bone parameter Vehicle AAV-LacZ AAV-cKL (3 × 1010) AAV-cKL (1 × 1011)
DF total BMD (mg/cm3) 344.4 ± 5.00 323.9 ± 19.59 227.8 ± 4.76A,B 217.4 ± 35.20A,B
DF total area (cm2) 0.0338 ± 0.0007 0.0384 ± 0.0048 0.0310 ± 0.002A 0.0311 ± 0.006
DF total BMC (mg) 1.05 ± 0.026 1.09 ± 0.049 0.638 ± 0.053A,B 0.605 ± 0.088A,B
MF total BMD (mg/cm3) 514.04 ± 6.79 498.6 ± 8.02 344.48 ± 21.11A,B 313.12 ± 29.68A,B
MF total area (cm2) 0.0170 ± 0.0002 0.0174 ± 0.0003 0.0152 ± 0.0004A,B 0.0160 ± 0.0004A,B
MF total BMC (mg) 0.7887 ± 0.017 0.7831 ± 0.02 0.4724 ± 0.03A,B 0.4539 ± 0.05A,B
LV total BMD (mg/cm3) 301.76 ± 9.50 367.78 ± 27.98A 227.54 ± 16.83 253.48 ± 21.60
LV total area (cm2) 0.0531 ± 0.001 0.0472 ± 0.004 0.0412 ± 0.004A 0.0227 ± 0.004A,B
LV total BMC (mg) 1.443 ± 0.06 1.5256 ± 0.08 0.8248 ± 0.07A,B 0.4845 ± 0.07A,B
DF, distal femur; MF, midshaft femur; LV, lumbar vertebra. n = 5 mice per group. AP < 0.05 vs. vehicle; BP < 0.05 vs. AAV-LacZ.
Figure 3
Ligand selectivity of cellular cKL activity. (A) NIH3T3 cells were treated with recombinant cKL or FGF23 alone or a combination of the two. 
FGF23 plus cKL potently increased cell survival (EC50, 1 nM) compared with either alone. (B) cKL prevented apoptosis in the presence of 
FGF23 but not FGF19 or FGF21 (*P < 0.05 vs. medium control). (C) Pretreatment of NIH3T3 cells with cKL and FGF23 in the presence of a 
pan-FGFR kinase inhibitor resulted in a significant decrease in cell survival. Cells maintained survival in the presence of the inactive isomer of 
the inhibitor (also with a reference control with FGF23 plus cKL [No inhibitor]). **P < 0.01 vs. inactive isomer. (A–C) Values are shown as mean 
± SEM. (D) Immunoblots for p-FGFR1 (arrow) and p-ERK1/2 in L6 cells transfected with FGFR1c, in the presence of the KL-independent ligand 
FGF2, compared with FGF21 or FGF23 in the presence or absence of cKL. FGF23 elicited FGFR signaling only in the presence of cKL (lanes 
were from the same gel but were noncontiguous).
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RNA isolation and qPCR 
Femur and kidney RNA were harvested using TRIzol (Life Technologies), and 
RNA samples were tested with primers specific for mouse Fgf23, Egr1, c-fos, 
Cyp27b1, Cyp24, Npt2a, and internal control β-actin as previously described 
(16). The TaqMan One-Step RT-PCR Kit (Life Technologies) was used to per-
form qPCR, and data were collected using the 7500 Real-Time PCR system 
and software (Life Technologies) and analyzed using the 2–ΔΔCT method.
Immunoblotting
Liver samples were homogenized in lysis buffer (Cell Signaling Technol-
ogy) on ice using a rotor-stator homogenizer. Immunoblot analysis was 
performed similar to that previously described (8), with 50 μg lysates 
per sample. Blots were acid stripped and reprobed with anti-actin-HRP 
(1:25,000; Sigma-Aldrich). L6-hFGFR1c cell lysates were blotted as 
described previously (15) and also probed with anti-phospho-ERK1/2 and 
anti–β-actin (Cell Signaling Technology).
Serum biochemistries 
Calcium and Inorganic Phosphorous Reagent Kits (Roche) were used for 
serum measurements in a Hitachi analyzer (Roche Diagnostics). Serum FGF23 
was tested using an “intact” FGF23 ELISA (Kainos Laboratories). Parathyroid 
hormone (PTH) was measured using a mouse-specific PTH ELISA (Immu-
topics International), and plasma cKL was quantified using a sandwich ELISA 
prepared with polyclonal antibodies recognizing the extracellular domain of 
mouse αKL (antibodies AF1819 and BAF1819; R&D Systems).
Statistics
Statistical analyses of the data were performed by 2-tailed Student’s t test, 
and significance for all tests was set at P < 0.05.
Study approval
Animal studies were approved by the Indiana University Institutional Ani-
mal Care and Use Committee and the internal review board at Eli Lilly and 
Company and are in accord with NIH guidelines for humane treatment of 
laboratory animals.
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Methods
Animal studies 
AAV was delivered to 8-week-old C57BL/6 mice via retro-orbital injection, 
which were then sacrificed by CO2 inhalation/bilateral pneumothorax or 
cervical dislocation for biochemical and histological analyses at the indi-
cated times (see the legends for Figures 1 and 2). Mice were retro-orbitally 
bled at interim time points. Separate cohorts were AAV-treated for 4 weeks 
for bone and kidney RNA analyses, as this time point coincided with the 
lowest serum phosphate concentrations.
Recombinant cKL and FGF23 and AAV-cKL production 
The cDNA encoding residues 35–983 of the extracellular domain of mouse 
αKL with a CD33 N-terminal signal sequence, or β-galactosidase gene 
(LacZ) as control, was packaged into a recombinant hybrid adeno-asso-
ciated viral vector 2/8 (AAV; RegenX Biosciences). In vivo expression was 
driven by a liver-specific thyroxine-binding globulin promoter. Recombi-
nant cKL and FGF23 protein were produced as previously reported (14) 
(provided by R. Micanovic, Eli Lilly and Company) or purchased as pre-
pared reagents (R&D Systems).
Cell culture and in vitro functional assays 
NIH3T3 cells were cultured according to the distributor’s specifications 
(ATCC). Cell survival was quantified at 72 hours using Resazurin (R&D 
Systems) according to manufacturer’s instructions. To measure apopto-
sis, cells were treated for 24 hours, and caspase-3/7 activity was quanti-
fied using the Caspase-Glo Kit (Promega). Cells were treated with the 
pan-FGFR inhibitor LY2874453 (biochemical IC50s for FGFR1 = 0.014 μM; 
FGFR2 = 0.0032 μM; FGFR3 = 0.0054 μM; and FGFR4 = 0.0495 μM) or its 
inactive isomer LY2202696 (provided by G. Zhao, Eli Lilly and Company). 
L6-hFGFR1c cells (from M. Malabunga, ImClone Systems Inc.) were pre-
pared and cultured as described previously (15). L6-hFGFR1c cells were 
pretreated with 1 μg/ml mouse αKL (R&D Systems) for 30 minutes and 
then stimulated with 100 ng/ml human FGF21 or FGF23 (R&D Systems) 
or 30 ng/ml FGF2 (Life Technologies) for 15 minutes.
Skeletal analyses 
Histomorphometry. Bones were preserved in 10% neutral-buffered formalin; 
bones were embedded in paraffin (decalcified) or methylmethacrylate, 
sectioned longitudinally, and stained with H&E or Goldners’ trichrome. 
Mineralized bone volume/tissue volume (BV/TV) and nonmineralized BV/
TV were assessed in a 2-mm region of the secondary spongiosa of the distal 
femur on Goldners’-stained methylmethacrylate sections.
CT analyses. Femora and vertebrae were analyzed by quantitative μCT 
using an LTC-100 CT scanner (Aloka). Scans of the femora were taken at 
2 and 10 mm from the end of the growth plate for distal metaphysis and 
midshaft analyses, respectively. BMC and bone area were calculated using 
Aloka software (SYS-C320 version 1.5); BMD was calculated as BMC nor-
malized to bone volumetric area.
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